17,261 trials
Knee Osteoarthritis
Primary: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC-A) — 22.5; 18.6; 18.9; 18.2 Score on a scale — p=.006
Melanoma
Primary: Overall Response Rate — 25.0 percentage of participants — p=<0.01
Psoriasis
Primary: Percentage of Participants Achiving PASI-75 at Week 12 — 3.6; 47.8; 80.8; 63.0 Percentage
Colorectal Cancer · Lung Cancer · Breast Cancer
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 Participants
Pain, Postoperative
Primary: Pain Intensity Visual Analog Scale (VAS)- 0-100 (0- no Pain and 100- Most Severe Pain) — 44; 41 score on a scale — p=0.156
Recurrent Lung Non-Small Cell Carcinoma · Stage II Lung Cancer AJCC v8 · Stage III Lung Cancer AJCC v8
Primary: Proportion of Participants With Progression Free Survival (PFS) — 0.6; 0.429 proportion of participants
Acute Coronary Syndrome
Primary: Percent Change in LDL-Cholesterol — -68.78; -27.58 percent change
Glioblastoma
Primary: Overall Survival (OS) — 8.0; 6.7; 7.5 Months
Pancreatic Adenocarcinoma
Primary: Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1…
Pruritus
Primary: Change in Peak Pruritus Numerical Rating Score (PRNS) — -3.1 score on a scale
T-cell Lymphoma · Angioimmunoblastic T-cell Lymphoma · Hepato-splenic T-cell Lymphoma
Primary: Overall Response Rate — 89.5 percentage of participants
Non-Alcoholic Fatty Liver Disease · Obesity · Obesity, Abdominal
Primary: Liver Fat Content — -5.3; 3.6 percent change in hepatic fat fraction
Thumb Carpometacarpal Osteoarthritis · Thumb Basal Joint Osteoarthritis
Primary: Subluxation of Thumb Carpometacarpal Joint as Per CAT Scan — .66 millimeters
Immunoglobulin A Nephropathy
Primary: Change in Urine Albumin-creatinine Ratio (UA/C) at Week 24 — -55.78 percent change
Multiple Myeloma
Primary: Number of Patients With Dose Limiting Toxicity — 0; 0; 0; 3 Participants